Crinetics Pharmaceuticals to Present Corporate and Clinical Update at 41st Annual J.P. Morgan Healthcare Conference
January 09, 2023 08:01 ET
|
Crinetics Pharmaceuticals, Inc.
Efforts to further increase commercial readiness ongoing as Phase 3 PATHFNDR trials of paltusotine in acromegaly approach topline data readouts which are expected in 2H 2023 Phase 2 trial of...
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 12, 2022 16:01 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on December 10, 2022, the Compensation Committee of Crinetics’ Board of Directors...
Crinetics Pharmaceuticals Provides Update on CRN04777 Program
November 28, 2022 08:00 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today provided an update on its development program for CRN04777, an investigational, oral somatostatin...
Crinetics Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference
November 22, 2022 08:00 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in a fireside chat and 1x1 investor meetings at...
Crinetics Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 14, 2022 08:00 ET
|
Crinetics Pharmaceuticals, Inc.
Paltusotine’s Phase 3 PATHFNDR-1 trial in acromegaly fully enrolled and on track for topline data in Q3 2023 Paltusotine lowered and maintained IGF-1 at levels comparable to prior injected SRL...
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 10, 2022 16:30 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on November 10, 2022, the Compensation Committee of Crinetics’ Board of Directors...
Enrollment Completed in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly
October 13, 2022 08:00 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the completion of enrollment in the Phase 3 PATHFNDR-1 study. PATHFNDR-1 is one of two...
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 10, 2022 16:57 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on October 10, 2022, the Compensation Committee of Crinetics’ Board of Directors...
Innovation Passport Granted for CRN04777 for the Treatment of Congenital Hyperinsulinism
October 06, 2022 08:00 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted...
Crinetics Pharmaceuticals Appoints Dana Pizzuti, M.D. as Chief Development Officer
October 03, 2022 08:00 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the appointment of Dana Pizzuti, M.D., as chief development officer. Dr. Pizzuti is a...